Cargando…
Effectors and potential targets selectively upregulated in human KRAS-mutant lung adenocarcinomas
Genetic and proteomic analysis of human tumor samples can provide an important compliment to information obtained from model systems. Here we examined protein and gene expression from the Cancer Genome and Proteome Atlases (TCGA and TCPA) to characterize proteins and protein-coding genes that are se...
Autores principales: | Li, Jinyu, Sordella, Raffaella, Powers, Scott |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908391/ https://www.ncbi.nlm.nih.gov/pubmed/27301828 http://dx.doi.org/10.1038/srep27891 |
Ejemplares similares
-
Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021) -
A combination therapy for KRAS-mutant lung cancer by targeting synthetic lethal partners of mutant KRAS
por: Pang, Xiufeng, et al.
Publicado: (2016) -
BRAF-Mutant Pulmonary Langerhans Cell Histiocytosis Mimicking Recurrence of Early-Stage KRAS-Mutant Lung Adenocarcinoma
por: Alden, Stephanie L., et al.
Publicado: (2020) -
Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors
por: Baldelli, Elisa, et al.
Publicado: (2015) -
KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma
por: Chen, Nan, et al.
Publicado: (2017)